The Weekly Roundup
This week, the 21st Century Cures Act sailed through the House and is headed to the Senate next week. The legislation will invest more than $6 billion in public health and medical research over the next decade. The bill, nearly 1,000 pages long, scratches at various funding mechanisms for medical research, revamps the FDA approval process, and would fund hundreds of vacant job requisitions at the agency, which has struggled to attract qualified candidates with competitive offers.
While it has substantial bipartisan support, there remain several highly vocal detractors, like Senator Elizabeth Warren, who refers to the bill as a Big Pharma giveaway and a danger to the public, and Dr. Michael Carome, director of Public Citizen’s Health Research Group, who said he was concerned about provisions that will allow for summaries of study data rather than full clinical trial records, which he believes could
"hide important information about the safety and effectiveness from the FDA scientist reviewing the data.”
But supporters point to what they describe as overwhelming benefits: faster time-to-market for drugs and devices, mental health reforms, and monies toward battling the opioid epidemic and Vice President Joe Biden’s “moonshot” project to cure cancer.
Here are few other stories that might be of interest:
- MDMA, aka “ecstasy,” has been observed to have a positive impact for treating the most challenged PTSD patients. What's next? Magic mushrooms?
- Want to up your game? Check out these 10 Best Practices in MTM.
- Plays well with others? Palliative care is another of the many roles in which a pharmacist can add value.
- Surprising results for high-dose testosterone blast. A new therapy helps some men overcome advanced prostate cancer.
- Too much, too fast. Retailers laud judicial block of proposed overtime reform.
- In case you missed it: There’s an interesting Alzheimer’s story developing in South America.
[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across each week. We hope you’ll share some of your favorites, too. Drop us a line at email@example.com.